阿昔洛韦联合胸腺肽和抗乙肝免疫核糖核酸抗乙肝病毒的疗效观察

本文报导阿昔洛韦对慢性乙肝的抗病毒疗效,其近期对HBeAg和HBV-DNA的阴转率为57.4％和63.6％,远期为45.4％和55.5％。如与胸腺肽和抗乙肝免疫核糖核酸联合应用能提高阴转率,其近期和远期分别为68.1％、71.4％和58.8％、61.5％。近期和远期抗病毒综合疗效单用阿昔洛韦组分别为57.6％和50.0％,而联合应用组则分别为67.2％和59.5％,与对照比较均有显著统计学意义。本资料还表明HBsAg、HBeAg和HBV-DNA三项全部阴转的患者其肝功能大多恢复正常,而持续阳性者则大多未能恢复正常,提示抗病毒治疗的重要性。

Effects of Acyclovir with Thymotide and Anti-HBiRNA in Anti-HBV

Asbtract:The effects of Acyclovir (ACV) for anti-HBV in patients with chronic hepatitis B were zeport-ed. The negative rates of near and far speriod for HBeAg and HBV-DNA were 57. 4% ,63. 6% and 45. 4% ,55. 5% zespectively. ACv with Thymotide and Anti-HBiRNA can improve negative rates which were 68. 15,71. 4% and 58. 8%, 61. 5% zespectively. The complex effects of anti-HBV betwwen ACV group and combined group in near and far speriod were 57. 6% ,50. 0% and 67. 2% ,59. 5% zespectively. They had obvious Statisti-cal significance. The data also show that the treated patients with negative HAsAg, HBeAg and HBV-DNA have more live function recovery,but thoes with positive have few it. These findings indicate the importance of anti-HBV thexapy.